The global type 1 diabetes market size accounted for USD 34.87 billion in 2024, grew to USD 37.6 billion in 2025 and is expected to be worth around USD 74.03 billion by 2034, registering a healthy CAGR of 7.82% between 2024 and 2034. The North America type 1 diabetes market size is predicted to increase from USD 16.04 billion in 2024 and is estimated to grow at a fastest CAGR of 7.92% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Type 1 Diabetes Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Type 1 Diabetes Market, by Insulin Analog, 2024-2034
8.1.1 Rapid-Acting Insulin
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Short-Acting Insulin
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Long-Acting Insulin
8.1.3.1. Market Revenue and Forecast (2021-2034)
9.1. Type 1 Diabetes Market, by Devices, 2024-2034
9.1.1. Insulin Pump
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Insulin Pen
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Blood Glucose Meter
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2034)
10.1. Type 1 Diabetes Market, by End-User, 2024-2034
10.1.1. Hospital
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Research Institutes
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Home Care
10.1.3.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Insulin Analog (2021-2034)
11.1.2. Market Revenue and Forecast, by Devices (2021-2034)
11.1.3. Market Revenue and Forecast, by End-User (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Insulin Analog (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Devices (2021-2034)
11.1.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Insulin Analog (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Devices (2021-2034)
11.1.5.3. Market Revenue and Forecast, by End-User (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Insulin Analog (2021-2034)
11.2.2. Market Revenue and Forecast, by Devices (2021-2034)
11.2.3. Market Revenue and Forecast, by End-User (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Insulin Analog (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Devices (2021-2034)
11.2.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Insulin Analog (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Devices (2021-2034)
11.2.5.3. Market Revenue and Forecast, by End-User (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Insulin Analog (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Devices (2021-2034)
11.2.6.3. Market Revenue and Forecast, by End-User (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Insulin Analog (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Devices (2021-2034)
11.2.7.3. Market Revenue and Forecast, by End-User (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Insulin Analog (2021-2034)
11.3.2. Market Revenue and Forecast, by Devices (2021-2034)
11.3.3. Market Revenue and Forecast, by End-User (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Insulin Analog (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Devices (2021-2034)
11.3.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Insulin Analog (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Devices (2021-2034)
11.3.5.3. Market Revenue and Forecast, by End-User (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Insulin Analog (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Devices (2021-2034)
11.3.6.3. Market Revenue and Forecast, by End-User (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Insulin Analog (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Devices (2021-2034)
11.3.7.3. Market Revenue and Forecast, by End-User (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Insulin Analog (2021-2034)
11.4.2. Market Revenue and Forecast, by Devices (2021-2034)
11.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Insulin Analog (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Devices (2021-2034)
11.4.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Insulin Analog (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Devices (2021-2034)
11.4.5.3. Market Revenue and Forecast, by End-User (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Insulin Analog (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Devices (2021-2034)
11.4.6.3. Market Revenue and Forecast, by End-User (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Insulin Analog (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Devices (2021-2034)
11.4.7.3. Market Revenue and Forecast, by End-User (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Insulin Analog (2021-2034)
11.5.2. Market Revenue and Forecast, by Devices (2021-2034)
11.5.3. Market Revenue and Forecast, by End-User (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Insulin Analog (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Devices (2021-2034)
11.5.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Insulin Analog (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Devices (2021-2034)
11.5.5.3. Market Revenue and Forecast, by End-User (2021-2034)
12.1. Eli Lilly
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Pfizer
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Abbott Laboratories
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. DiaVasc, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Biodel, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Sanofi
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Merck
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Astellas Pharma
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Mannkind Corporation
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample